{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:03:01Z","timestamp":1788458581498,"version":"build-2803163510"},"reference-count":27,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s332026","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T02:54:51Z","timestamp":1634266491000},"page":"4371-4382","source":"Crossref","is-referenced-by-count":18,"title":["The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"David P","family":"Walling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A","family":"Hassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-1850","authenticated-orcid":true,"given":"Lourdes","family":"Anta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-9194","authenticated-orcid":true,"given":"Ibon","family":"Gutierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4088\/JCP.v67n0317","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/YIC.0000000000000139","volume":"31","author":"Llaud\u00f3","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"ref5","first-page":"9","volume":"33","author":"Anta","year":"2018","journal-title":"Int Clin Psychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s40263-020-00762-0","volume":"34","author":"Anta","year":"2020","journal-title":"CNS Drugs"},{"key":"ref7","volume-title":"The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology","year":"1976a"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry"},{"key":"ref9","volume-title":"Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology","year":"1976b"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"1970","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1208\/s12248-008-9014-y","volume":"10","author":"Maganti","year":"2008","journal-title":"AAPS J"},{"key":"ref13","unstructured":"Newlands A. Statistics and pharmacokinetics in clinical pharmacology studies (paper ST03). Presented at: SAS Conference Proceedings: pharmaceutical Users Software Exchange; PhUSE Dublin; 9\u201311 October; 2006; Dublin, Ireland."},{"key":"ref14","first-page":"829","volume":"25","author":"Samtani","year":"2011","journal-title":"CNS Drugs"},{"key":"ref15","unstructured":"Xeplion\u00ae summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeplion-epar-product-information_en.pdf. Accessed July 20, 2021."},{"key":"ref16","unstructured":"Abilify maintena\u00ae summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abilify-maintena-epar-product-information_en.pdf. Accessed July 20, 2021."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1461145709990988","volume":"13","author":"Kramer","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref18","unstructured":"Aristada Full Prescribing Information. Available from: https:\/\/www.aristadahcp.com\/downloadables\/ARISTADA-INITIO-PI.pdf. Accessed July 26, 2021."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1055\/s-2000-7969","volume":"33","author":"Tavcar","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"ref20","first-page":"50","volume":"45","author":"Ereshefsky","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"ref21","unstructured":"Risperdal\u00ae (oral risperidone) [prescribing information]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020272s085,020588s072,021444s058lbl.pdf. Accessed July 1, 2021."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/026988119701100116","volume":"11","author":"Song","year":"1997","journal-title":"J Psychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.npp.1301409","volume":"33","author":"Mamo","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/0091270009355156","volume":"50","author":"Thyssen","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/0269881107088435","volume":"22","author":"Bushe","year":"2008","journal-title":"J Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=74980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=74980","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T02:57:20Z","timestamp":1634266640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-steady-state-comparative-bioavailability-of-intramuscular-risperid-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"URL":"https:\/\/doi.org\/10.2147\/dddt.s332026","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}